Dingdang Health Technology Group Ltd. reported a share buy-back of 784,000 ordinary shares on 21 October 2026, executed on the Hong Kong Stock Exchange under its existing repurchase mandate approved on 23 June 2026. The transactions were completed at prices ranging between HKD 0.87 and HKD 0.90 per share, translating to a volume-weighted average cost of HKD 0.8827 and an aggregate consideration of HKD 0.69 million.
Following the purchase, Dingdang Health’s issued share capital (excluding treasury shares) fell marginally by 0.06% to 1.23 billion shares, down from 1.23 billion on 20 October 2026. Concurrently, the company’s treasury stock increased to 14.31 million shares, while total issued shares remained unchanged at 1.24 billion, as none of the repurchased shares have yet been cancelled.
Since receiving shareholder authorisation, the company has bought back a cumulative 17.17 million shares, equivalent to 1.38% of the share count outstanding on the authorisation date, against a maximum mandate of 124.32 million shares. Under Hong Kong listing regulations, Dingdang Health is restricted from issuing new shares or disposing of treasury shares until 20 November 2026.
Comments